




Treatment of primary angle closure: What do the trials tell us?

Winifred Nolan FRCOphth MD

Consultant Ophthalmologist Glaucoma Service Moorfields Eye Hospital, London

Angle closure: Definitions Standardised definitions of disease (ISGEO 2002)



Angle closure: Management

Stages

- Acute angle closure
- Primary angle closure
- Primary angle closure glaucoma
- Asymptomatic narrow angles (ITC)

Treatment options

- Laser iridotomy
- Surgical iridectomy
- Iridoplasty
- Lens extraction
- Trabeculectomy
- Drops

Acute angle closure - Management

Acute attack broken

Oral diamox qds
Topical IOP lowering treatment
Topical steroid 2 hrly
Pilocarpine both eyes


Laser iridotomy BOTH EYES


Acute attack not broken

Diamox/
Mannitol iv Iridoplasty

WGA consensus statement:

"Laser iridotomy should be performed as soon as feasible in the affected eye(s), and should also be performed as soon as possible in the contralateral eye"





Asymptomatic narrow angles (Iridotrabecular contact)

Treatment options:

- 1. Observe
- 2. Laser iridotomy

Laser peripheral iridotomy

Evidence supporting iridotomy?

Good evidence that protects eyes against acute angle closure

Fellow eye data: Caucasian eyes
 50% untreated → APAC
 2% iridectomy → APAC

Fellow eye data: Asian eyes

No APAC in 71 fellow eyes treated with PI at 4 years

Lowe RF, Snow JT Ang L, 2000

Laser peripheral iridotomy for the prevention of angle closure: a single-centre, randomised controlled trial

Mingguang He, Yuzhen Jiang, Shengsong Huang, Dolly S Chang, Beatriz Munoz, Tin Aung, Paul J Foster*, David S Friedman

- · Guangzhou, China
- Randomised controlled trial
- Subjects 50-70 years old
- Asymptomatic narrow angle (ITC in 2 or more quadrants)
- Identified through community screening
- Randomised one eye to laser iridotomy and fellow eye control

Primary outcome:

- Incident primary angle closure disease: elevated IOP, PAS or AAC
- Follow up 6 years

Lancet 2019; 393: 1609-18

Results

| | | Laser peripheral iridotomy | | |
|---------|-------------|----------------------------|----------|-------|
| | | No endpoint | Endpoint | Total |
| | No endpoint | 844 | 9 | 853 |
| Control | Endpoint | 26 | 10 | 36 |
| | Total | 870 | 19 | 889 |

Figure 2: Pair-wise analyses of primary endpoint (intention-to-treat analysis) at 72 months

p=0-0041 with McNemar's test.


4.19 per 1000 eye-years (PI) 7.97 per 1000 eye-years (control)

Hazard ratio = 0.53 (95% CI: 0.3-0.92, p =0.024) No sight –threatening events

Baseline Findings associated with endpoint

| | Eyes that did reach endpoint, n=55, 3% | Eyes that did not reach endpoint, n=1723, 97% | Hazard ratio (95% CI) | pvalue |
|--|--|--|--|-------------------------|
| Univariate model | | | | |
| Randomly assigned to laser peripheral Iridotomy | 34-5% | 50-5% | 0-53 (0-30-0-92) | 0-024 |
| Multivariate models | | | | |
| Age, years (per 1 year older) | 60-91 (5-76) | 59-25 (4-97) | 1.07 (1.01-1.13) | 0.015 |
| Female (vs male) | 81-8% | 82.9% | 1-11 (0-55-2-24) | 0.765 |
| Randomly assigned to laser peripheral Iridotomy (vs control) | 34-5% | 50-5% | 0-52 (0-30-0-91) | 0-023 |
| Baseline intraocular pressure, mm Hg (per 1 mm Hg increase) | 15:76 (3:02) | 15-06 (2-83) | 1-09 (0-99-1-19) | 0.075 |
| Total angle width*, score (per 1 score higher) | 4-80 (2-37) | 5-36 (2-38) | 0-91 (0-82-1-02) | 0-098 |
| Limbal anterior chamber depth†, % (per 10% higher) | 18-64 (8-41) | 22-28 (7-57) | 0-49 (0-34-0-71) | <0.001 |
| Central anterior chamber depth‡, mm (per 1 mm deeper) | 2-47 (0-24) | 2:55 (0:22) | 0-21 (0-06-0-72) | 0-013 |
| Lens thickness‡, mm (per 1 mm thicker) | 4.95 (0.37) | 4-87 (0-32) | 1-57 (0-65-3-79) | 0.318 |
| Dark room prone provocative test, mm Hg (per 1 mm Hg increase) | 3:76 (3:39) | 4-27 (2-97) | 0-94 (0-86-1-03) | 0-199 |
| All values are mean (SD) unless stated otherw peripheral indotomy, age, gender, baseline in calculated by the sum of Shafer grading of all H_limbal anterior chamber depth was evaluate lens thickness were measured by ultrasound A | traocular pressure four quadrants (ra ed by modified var | , and variables of i ange from 0 to 16, | nterest. *Total angle wi larger number indicate | idth was swider angl |

Singapore Asymptomatic narrow angles laser iridotomy study (ANA-LIS)



Progression = PAS, ♠iop, acute attack, symptomatic angle closure, PACG 2 AAC in observation group, one in PI group

NNT to prevent progression = 20.7

Baskaran M, Sasikumar R, Wong HT et al. ARVO 2016

Impact on clinical practice

- Incidence of angle closure disease in individuals with asymptomatic narrow angles is <u>very low</u>
- Benefit of prophylactic iridotomy is limited
- Laser iridotomy for all narrow angle patients is NOT indicated
- Assess risk factors and discuss with patient:
- Diabetics/ frequent mydriatic exam
- Angle width and mechanism
- Family history of AAC
- Other medications eg anti anxiety medication
- Clinical judgement

Example: 53 yr old man

Left amblyopia, 270 ° ITC both eyes

Mother Acute angle closure

Offer PI




Example: 64 yr old woman

ITC one quadrant

Early cataract

Watch




PAC and PACG


Treatment options:


- 1. Laser iridotomy
- 2. Laser iridoplasty
- 3. Eye drops
- 4. Lens extraction

Argon laser peripheral iridoplasty



Lens extraction







Inclusion criteria

- PACG with IOP ≥ 21 mmHg or Previous acute angle closure PAC with IOP ≥ 30 mmHg
- At least 180 degrees of angle closure
- Newly diagnosed (up to 6 months)
- Age ≥ 50 years
- Phakic in affected eye (no cataract)


Exclusion criteria

- Severe glaucoma (C/D ratio ≥ 0.9 or $MD \ge 15 dB$
- · Symptomatic cataract
- Axial length ≤ 19 mm (nanophthalmos)
- Previous surgery (IOL, laser iridotomy)
- · Increased surgical risk



Primary outcome

- Patient-centred: Health status (EQ-5D)
- Clinical: IOP
- Cost-effectiveness



eagle

Baseline characteristics (n=419)

• Race: Chinese = 121 (29%)


• **Age:** 67.0 (+/- 9.8) years


• **EQ-5D:** 0.871 (+/- 0.18)

• **Diagnosis:** PAC= 157 (37%), PACG = 261 (62%)

• **IOP:** 28.9 (+/- 9.7) mmHg

Humphrey MD: -4.2 (+/-6.0) dB







Primary clinical outcome: IOP

| | L | ens extraction | | Laser PI | |
|----------------|-----|-------------------|-----|-------------------|-----------|
| IOP (mmHg) | N | mean (SD) | N | mean (SD) | |
| Baseline IOP | 208 | 29-5(8-2) | 211 | 30-3(8-1) | |
| 36 months IOP* | 182 | 16-6 (3-5) | 184 | 17-9 (4-1) | p = 0.004 |
| | | | | | |

^{*}Includes patients who had glaucoma surgery during the 3-year follow-up



| Number of | Lens Extraction | Laser PI |
|----------------------|-----------------|------------|
| medications | | |
| 0 medications, N (%) | 126 (60-6%) | 45 (21-3%) |
| 1 medications, N (%) | 33 (15.9%) | 67 (31-8%) |
| 2 medications, N (%) | 15 (7·2%) | 46 (21-8%) |
| 3 medications, N (%) | 3 (1.4%) | 19 (9.0%) |
| 4 medications, N (%) | 1 (0.5%) | 4 (1.9%) |
| Mean ± SD | 0-4 ± 0-8 | 1·3 ± 1·0 |



eagle Intra-operative* complications

| | Lens extraction N=208 | Laser PI N=211 |
|-------------------------------------|--------------------------|-------------------|
| Posterior capsule rupture | 2 (1.0%) | |
| Iris prolapse | 2 (1.0%) | |
| Vitreous loss | 1 (0.5%) | |
| Broken haptic | 1 (0.5%) | |
| Bleeding or haemorrhage | | 16 (7.6%) |
| *Pre-operative attack angle closure | 1 (0-5%) | |



eagle Post-operative complications

| | Lens extraction (N=208) | Laser PI (N=211) |
|--------------------------------|-------------------------|------------------|
| Flat anterior chamber | 2 (1.0%) | 1 (0.5%) |
| Retinal detachment or tear | | 1 (0.5%) |
| Malignant glaucoma | 1 (0.5%) | 2 (1.0%) |
| Corneal decompensation | 1 (0.5%) | |
| Macular Oedema | 5 (2·4%) | 3 (1.4%) |
| IOP spike | 2 (1.0%) | 5 (2.4%) |
| Post-operative inflammation | 5 (2·4%) | 1 (0.5%) |
| Central retinal vein occlusion | | 1 (0.5%) |
| Dysphotopsia | | 1 (0.5%) |
| Posterior vitreous detachment | | 1 (0.5%) |
| Macular hole | 1 (0.5%) | |



Conclusion

- Initial lens extraction for PACG and PAC with high IOP (>30mmHg) is associated with better clinical and patient-reported outcomes than laser PI
- Initial lens extraction for PACG and PAC with high IOP is likely to be costeffective
- Lens extraction has a risk of PC rupture and other complications: individualised decision making!
- (EAGLE does not support that we must do lens extraction in all, it is an option)
- EAGLE results not applicable to ITC (Asymptomatic narrow angles only)
- Note IOP cut off of >30mmHg for PAC patients if IOP <30 discuss with patient

The effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma: a randomized controlled trial (EAGLE). The Lancet, 2016


Summary - Indications for iridotomy


- Acute angle closure affected and fellow eye
- ITC particularly high risk patients:
 - Diabetic
 - Family History
 - Travel frequently
- PAC with IOP <30mmHg (not fulfilling EAGLE criteria)
- PAC > 30mmHg and patient does not want surgery

Indications for lens/ cataract surgery

- Symptomatic cataract
- PACG with IOP > 21mmHg RE
- PAC with IOP >30mmHg
- · Refractory or recurrent acute or subacute angle closure

Is there a role for trabeculectomy in PACG?





Summary - Advanced PACG, non- pupil block

- Age → Young (34)
- Lens status → Clear
- PAS extent, onset → extensive, onset unknown
- Glaucomatous optic neuropathy → Advanced
- Chronicity of disease → Chronic
- Refractive error → None
- Biometry → AL 23.4 mm
- Mechanism of angle closure → Plateau/ iris cysts
- Patient circumstances and wishes → foreign service

Tips for trabeculectomy in angle closure

- Counsel patient re complications/ aqueous misdirection
- GA anaesthesia if small eye /high IOP
- Anterior chamber maintainer
- 3 4 tight releasable sutures
- No flow on table
- AC deep and formed at end of surgery
- Atropine at end of surgery

Challenging case - 74 yr old man

- 2nd opinion
- West African
- Advanced PACG
- Left phaco → CMO
- Patient delayed intervention RE
- Maximum drops + Diamox
- + 5.0 D hypermetrope

